# Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference Canonical URL: https://biopharmsignal.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-9th-annual-mash-investor--0f3c9d8b Ticker: GALT Company: Galectin Therapeutics Source: Galectin Therapeutics Published: 2025-10-20 12:00 EST ## Summary Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin... ## Article Body Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 9 th Annual MASH Virtual Investor Conference, taking place October 21, 2025. H.C. Wainwright 9 th Annual MASH Investor Conference Company presentation: October 21, 2025, at 7:00 AM ET Webcast: here The live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company’s website. Additionally, the Galectin management team, including Joel Lewis, Chief Executive Officer, and Khurram Jamil, M.D., Chief Medical Officer, will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com . Company Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com Investors Relations Contact: Kevin Gardner kgardner@lifesciadvisors.com Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin. ## Recent Company News - 2026-06-23 12:00 EST — [Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension](https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-positive-type-c-meeting-with-the-fda-for-belapec-a0feb2ff) — Source: Galectin Therapeutics - 2026-05-27 12:00 EST — [Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis](https://biopharmsignal.com/news/GALT/galectin-therapeutics-presents-new-easl-2026-oral-and-poster-analyses-demonstrat-c8e53529) — Source: Galectin Therapeutics - 2026-05-15 12:00 EST — [Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-march-31-2026-financial-results-and-provides-busin-a4c2539c) — Source: Galectin Therapeutics - 2026-05-11 12:00 EST — [Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology](https://biopharmsignal.com/news/GALT/galectin-therapeutics-announces-publication-of-navigate-phase-2b-trial-results-f-81825c4e) — Source: Galectin Therapeutics - 2026-03-31 12:00 EST — [Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GALT/galectin-therapeutics-reports-2025-financial-results-and-provides-business-updat-21c93220) — Source: Galectin Therapeutics ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)